source
- GLP-1 drugs shift from obesity treatment to lifestyle products, prompting setbacks for Merck and DaiichiThe column notes that GLP-1 medicines, originally marketed to treat obesity as a medical condition, are now being promoted more as general lifestyle enhancers for appearance and wellbeing. Novo No…
- Biopharma chases new immunology targets as Humira and Dupixent set high barJohnson & Johnson, Pfizer, Argenx and several other companies are expanding their immunology pipelines, seeking new targets and improvements to capture part of the market driven by AbbVie’s Humira…